Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-IMG-172714

Xenbase Image ID: 172714


Fig. S1 (related to Fig. 1). MO-mediated depletion of KDM3A and assessment of the function of KDM3A in the developmental potential of naïve ectoderm. (A) Schematic depiction of the start codon spanning sequence of KDM3A CDS and the KDM3A MO target sequence. The sequence of a 5mis-match mutant version of KDM3A MO, designed cMO, shown in comparison with the KDM3A MO. (B) qPCR analyses of gene expression in animal cap explants. cMO: 80ng; 3A MO: 80ng. Noggin mRNA: 200 pg. WE: whole embryo; AC: animal cap explants. ns: no significance according to two-tailed Student t-test. (C) Animal cap explants treated with or without Activin protein. 80ng cMO and 3A MO were injected into the animal pole at the 2-cellstage and animal caps were dissected at the stage 8.5 and treated with or without Activin (5 ng/ml) for four hours. All explants were then cultured in simple saline to the sibling stage 18. (D, E) Western blot data showing that KDM3A MO/MO2 injection did not affect the expression of microinjected 6MT-Neurog2 (D) or 6MT-Ascl1 (E). cMO: 80 ng; 3A MO: 80 ng; 3A MO2: 80 ng. 6MT-neurog2 mRNA: 500 pg; MT-ascl1: 200 pg. MO and mRNA were sequentially injected into both cells at the 2-cell stage. Embryos were lysed at stage 11.

Image published in: Lin H et al. (2017)

Copyright © 2017. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.

Larger Image
Printer Friendly View

Return to previous page